The trial’s secondary endpoints assessed drug activity and efficacy and Antisense said it was “highly encouraged” that data to date is indicative of drug effect, “particularly considering the small number of patients evaluated and that the progress of the final three patients (due to complete dosing in November) appears consistent with this view that the drug is showing activity”.
ANP Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
